ATC Group: N04BC01 Bromocriptine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N04BC01 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N04 Anti-parkinson drugs
3 N04B Dopaminergic agents
4 N04BC Dopamine agonists
5 N04BC01 Bromocriptine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 40 mg

Active ingredients in N04BC01

Active Ingredient Description
Bromocriptine

Bromocriptine is an inhibitor of prolactin secretion and a stimulator of dopamine receptors. The areas of application of bromocriptine are divided into endocrinological and neurological indications.

Related product monographs

Title Information Source Document Type  
BRAMESTON Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
PARLODEL Capsule Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Brazil (BR)

Cyprus (CY)

Estonia (EE)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Italy (IT)

Japan (JP)

Malta (MT)

Netherlands (NL)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.